Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Insecticides India Ltd

| Q2 FY26 Earnings Conference Call

NEUTRAL SENTIMENT

Report Source

⬤12th Nov 25

Summary : Insecticides (India) Limited navigated a challenging Q2 with new product launches and strategic partnerships, maintaining a positive outlook for H2 recovery despite inventory and competition concerns.

Management Perspective positive : We are very, very hopeful that we are going to make a reasonable recovery in H2 of this year. I am very, very hopeful that from here, we'll grow continuously with our efforts. I am very confident that the type of relationship and continuous effort we are making to touch base the farmer is going to help us and support us.

Concall Report Analysis & Insights

Business Overview

  1. IIL maintained business momentum despite a challenging Q2 monsoon season.
  2. Core portfolio remained resilient, supported by strong distribution and brand equity.
  3. Launched five new products, including patented Altair (herbicide) and Sparcle (insecticide).
  4. Collaboration with Corteva Agriscience brings advanced agriculture technologies to farmers.
  5. Focus on profitable growth, premiumization, and maintaining EBITDA margins.

Future Growth Prospects

  1. Optimistic about improving market share and scaling export footprint.
  2. Expanding R&D pipeline with new combination molecules and technical collaborations.
  3. New leadership appointment (COO) to drive manufacturing and supply chain expansions.
  4. Focus on innovation, premiumization, and becoming a complete crop solution provider.
  5. Expects continuous growth and improved performance over the next 2-3 years.

Management Insights

  1. Q2 monsoon was challenging, but global demand shows stabilization.
  2. Launched five new products, including patented Altair and Sparcle, with high hopes.
  3. Collaboration with Corteva Agriscience is a significant step for technology transfer.
  4. Achieved 2% revenue growth and 11% gross profit growth in Q2 FY26.
  5. Expects a reasonable recovery in H2, supported by favorable Rabi season conditions.

Signs of Skepticism

  1. Inventory target of Rs. 600 crores by year-end looks difficult, now crossing Rs. 700 crores.
  2. EBITDA margin remained subdued despite gross margin improvement due to increased expenses.
  3. Volume growth in Focus Maharatna and Maharatna segments was negligible in H1.
  4. Company acknowledged that competition for off-patented molecules now appears within 6 months, faster than 2-3 years previously.
  5. Difficult to predict if Q3 or Q4 will be bigger due to varying regional situations.

Risk Factors

  1. Challenging monsoon in Q2 led to disrupted agronomic activities and crop damage.
  2. Agrochemical demand remained subdued in the domestic market.
  3. Significant sales returns of Rs. 150 crores due to adverse weather conditions.
  4. Slower debtor recovery impacted PAT due to tough market conditions.
  5. Increased competition for off-patented molecules, now appearing within 6 months.

Good To Know

  1. B2C sales were 77%, B2B 19%, and exports 4% in Q2 FY26.
  2. Working on ESG initiatives: effective natural resource usage, reduced carbon footprint, zero-discharge plants.
  3. Appointed Mr. Devendra Ray as COO to oversee manufacturing, expansion, and supply chain.
  4. Increased field promotion activities and farmer engagement, reaching over 100,000 farmers.
  5. R&D centers in Chopanki and Dahej are developing new molecules and formulations.

Key Drivers

  1. New product launches drive growth.
  2. Favorable Rabi season boosts demand.
  3. Corteva partnership expands technology.
  4. Export market scaling up.

Key Analyst Discussions

Competitive Environment

  1. Maintained sales better than competitors due to increased market presence and specialty products.
  2. Focus on identifying portfolio gaps and farmer needs to offer complete solutions.
  3. New product launches face competition within 6 months, requiring continuous innovation.
  4. Backward integration efforts are continuous to maintain competitiveness and margins.
  5. Aim to bring new products into the Maharatna segment with 35%+ margins.

Market Trends & Consumer Behavior

  1. Monsoon started positive but turned challenging in Q2 with heavy rains and crop damage.
  2. Extended rainfall created good soil moisture, supporting a favorable Rabi season.
  3. Wheat, pulses, and paddy sowing expected to increase due to water availability.
  4. Farmer sentiment is positive for the upcoming Rabi season despite Kharif losses.
  5. Overall market situation is positive, but localized crop losses occurred in some areas.

Financial Highlights

  1. Q2 revenue increased 2% to Rs. 638 crores, gross profit up 11% to Rs. 220 crores.
  2. PAT decreased from Rs. 61 crores to Rs. 59 crores due to financial costs and slow debtor recovery.
  3. Overhead expenses increased due to field promotion activities and forex losses (Rs. 2 crores).
  4. Gross margin improved due to higher sales of Maharatna and generic products.
  5. H1 EBITDA margin was 13%, with management aiming for continuous improvement.

Product Composition

  1. Launched five new products in Q2, including Altair, Sparcle, Amuse, Centran SC, and Brahmos.
  2. Focus on specialty products and premiumization to improve margins.
  3. Aiming for 70% of product portfolio from own captive technicals in 2-3 years.
  4. Continuously developing new formulations and molecules getting off-patent.
  5. Introducing 3-4 new active ingredients (Als) annually, focusing on Maharatna segment.

Strategic Considerations

  1. New COO will manage manufacturing expansions, including a new SEZ facility.
  2. Exploring CRAM activities and international tie-ups with large companies.
  3. Targeting double-digit revenue growth for FY26, especially in Focus Maharatna.
  4. Export growth is positive, aiming to reach Rs. 150 crores again.
  5. Backward integration is a continuous effort, starting from basic stages for competitiveness.